
1 Supplementary Figure S 1. Study design. Panel A: Fifteen subjects with established ESRD 2 receiving thrice weekly hemodialysis were randomly assigned, in a paired, single-blinded 3 fashion, to receive either a 250 mg vancomycin or placebo capsule weekly. At 3 months, 4 the subjects were crossed-over and either received placebo or vancomycin for another 3 5 months. Pre-dialysis blood samples were collected weekly for one month and then 6 monthly. Stool samples were collected at baseline and then monthly. Panel B: Summary of 7 subject's samples included in each analysis. 8 9 Supplementary Figure S2. Changes in concentration of solutes from 10 subjects (126 10 samples) over the 12-week treatment periods. Box and whisker plots are shown. 11 12 Supplementary Figure S3. Vancomycin-related changes in relative abundance of 13 genera. Bar plot of the relative abundance of the top 10 most abundant genera at 14 baseline and 4 weeks of antibiotics in each subjects. Samples rarefied to 1000. 15 16 Supplementary Figure S4. IS recovery after 12 weeks vancomycin. Black line is fitted 17 mixed model. 18 19

1 Suppl. Fig. S1

Α

2

3



Baseline Receiving Receiving Placebo

S: Solutes M: Microbiome

M: Samples included in DESeq2 analysis

*: stool samples included in the diversity analysis IT: stool samples included in the recovery analysis

Weeks Subjects	0	1			4	8	12	13			16	20	24
RRA1	SM*	S	S	S	SM*	SM*	SM* ^π	S	S	S	SM ^π	SM	SM^{T}
RRA2	SM*	S	S	S	SM*	SM*	S	S	S	S	S	S	S
RRA4	SM*	S	S	S	SM*	SM*	S M * ^π	S	S	S	SM ^π	SM	SM^{π}
RRA5	SM*	S	S	S	S	SM*	SM* ^π	S	S				
RRA8	SM*	S	S	S	SM*	SM*	SM* ^π	S	S	S	SM ^π	SM^{π}	SM^{π}
RRZ1	SM*	S	S	S	SM*	SM*	SM*	S	S	S	SM*	SM*	SM*
RRZ3	SM*	S	S	S	SM*	SM*	S	S	S	S	SM*	SM*	SM*
RRZ4	SM*	S	S	S	SM*	S	S	S	S	S	S	SM*	SM*
RRZ5	SM*	S	S	S	SM*	SM*	SM*	S	S	S	SM*	S	SM*
RRZ6	SM*	S	S	S	SM*	SM*	SM*	S	S	S	SM*	SM*	SM*


All SM samples were included in the solutes and microbiome correlation analysis

4 5 6


7

1 Suppl. Fig. S2

Solutes with Significant Declines in Concentration During Vancomycin Administration




Solutes with Non-significant Changes in Concentration During Vancomycin Administration



Significant declines as assessed by mixed models analysis in Results

3 Suppl. Fig. S3


2



Suppl. Fig. S4

4 5

6



)		
)		

Table S1: Vancomycin-related changes in relative abundance of genera							
Genus	n	avwk0	avwk4	difference	SE.diff	Paired.t.pval	
Prevotella	7	0.067	0.008	-0.058	0.038	0.177	
Clostridium	7	0.075	0.033	-0.041	0.05	0.439	
Bacteroides	7	0.130	0.094	-0.037	0.021	0.134	
Faecalibacterium	7	0.063	0.050	-0.013	0.018	0.506	
Ruminococcus	7	0.023	0.019	-0.003	0.009	0.742	
Akkermansia	7	0.094	0.095	0.001	0.056	0.985	
[Ruminococcus]	7	0.032	0.036	0.005	0.016	0.775	
Proteus	7	0.013	0.028	0.015	0.015	0.356	
[Eubacterium]	7	0.008	0.042	0.034	0.016	0.078	
Alistipes	7	0.013	0.080	0.067	0.049	0.224	

avwk 0: average relative abundance at week 0 SE.diff: standard error difference

Paired.t.pval: p value from paired test comparing 0 and 4 weeks relative abundance.